Abstract
ß-Blockers are a recommended therapy in patients with acute myocardial infarction and coronary artery disease. ß-Blockers markedly and unequivocally reduce mortality in patients with myocardial infarction and coronary artery disease with heart failure and a reduced ejection fraction. However, the mortality effects of ß-blockers in patients with a preserved ejection fraction are not established even though they represent the majority of patients with coronary artery disease. In this review, we will assess the evidence basis of the recommendations for ß-blockers in the US guidelines and discuss emerging concerns about the use of ß-blockers and other heart rate-lowering medications in patients with a preserved ejection fraction that suggest that their long-term adverse outcomes may outweigh their antianginal benefits.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 262-270 |
| Number of pages | 9 |
| Journal | Coronary Artery Disease |
| Volume | 29 |
| Issue number | 3 |
| DOIs | |
| State | Published - 2018 |
| Externally published | Yes |
Bibliographical note
Funding Information:This work was supported by the National Institutes of Health R01 HL-122744 (M. Meyer).
Publisher Copyright:
© 2018 Wolters Kluwer Health, Inc.
Keywords
- Adrenergic ß-receptor antagonist
- Coronary artery disease
- Heart rate
- Myocardial infarction
